Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure

@article{Sendi2007CostEffectivenessOG,
  title={Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure},
  author={Pedram Sendi and Huldrych F. G{\"u}nthard and Mathew Simcock and Bruno Ledergerber and J{\"o}rg Sch{\"u}pbach and Manuel Battegay},
  journal={PLoS ONE},
  year={2007},
  volume={2},
  pages={853 - 860}
}
BACKGROUND Genotypic antiretroviral resistance testing (GRT) in HIV infection with drug resistant virus is recommended to optimize antiretroviral therapy, in particular in patients with virological failure. We estimated the clinical effect, cost and cost-effectiveness of using GRT as compared to expert opinion in patients with antiretroviral treatment failure. METHODS We developed a mathematical model of HIV disease to describe disease progression in HIV-infected patients with treatment… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 55 references

Genotypic and phenotypic resistance patterns at virological failure in a simplification trial with nevirapine, efavirenz or abacavir

  • DE Ochoa, M Arnedo, M Xercavins
  • AIDS
  • 2005

Incremental costeffectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET)

  • C Kaiser, HP Brunner-La Rocca, PT Buser
  • Lancet
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…